• Education
    • Higher Education
    • Scholarships & Grants
    • Online Learning
    • School Reforms
    • Research & Innovation
  • Lifestyle
    • Travel
    • Food & Drink
    • Fashion & Beauty
    • Home & Living
    • Relationships & Family
  • Technology & Startups
    • Software & Apps
    • Startup Success Stories
    • Startups & Innovations
    • Tech Regulations
    • Venture Capital
    • Artificial Intelligence
    • Cybersecurity
    • Emerging Technologies
    • Gadgets & Devices
    • Industry Analysis
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy
Today Headline
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
  • Home
  • World News
    • Us & Canada
    • Europe
    • Asia
    • Africa
    • Middle East
  • Politics
    • Elections
    • Political Parties
    • Government Policies
    • International Relations
    • Legislative News
  • Business & Finance
    • Market Trends
    • Stock Market
    • Entrepreneurship
    • Corporate News
    • Economic Policies
  • Science & Environment
    • Space Exploration
    • Climate Change
    • Wildlife & Conservation
    • Environmental Policies
    • Medical Research
  • Health
    • Public Health
    • Mental Health
    • Medical Breakthroughs
    • Fitness & Nutrition
    • Pandemic Updates
  • Sports
    • Football
    • Basketball
    • Tennis
    • Olympics
    • Motorsport
  • Entertainment
    • Movies
    • Music
    • TV & Streaming
    • Celebrity News
    • Awards & Festivals
  • Crime & Justice
    • Court Cases
    • Cybercrime
    • Policing
    • Criminal Investigations
    • Legal Reforms
No Result
View All Result
Today Headline
No Result
View All Result
Home Science & Environment Medical Research

Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

August 1, 2025
in Medical Research
Reading Time: 2 mins read
A A
0
Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis
3
SHARES
6
VIEWS
Share on FacebookShare on Twitter


Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

For patients with eosinophilic granulomatosis with polyangiitis (EGPA), rituximab is not superior to the conventional remission induction strategy, according to a study published online July 29 in the Annals of Internal Medicine.

Benjamin Terrier, M.D., Ph.D., from Hôpital Cochin in Paris, and colleagues compared rituximab to a conventional strategy for the induction of remission in patients with EGPA in a phase 3, multicenter superiority trial. Patients with a diagnosis of EGPA, newly diagnosed or relapsing disease at the time of screening, were included and randomly assigned in double-blind fashion to receive glucocorticoids plus rituximab versus the conventional strategy of glucocorticoids alone or in combination with cyclophosphamide in severe forms. The primary end point was remission, defined as a Birmingham Vasculitis Activity Score of 0 and a prednisone dose of 7.5 mg/day or less at day 180.

One hundred five participants were randomly assigned. The researchers found that 63.5% and 60.4% of patients in the rituximab and control groups, respectively, achieved the primary end point (relative risk, 1.05; 95% confidence interval, 0.78 to 1.42; P = 0.75).

Similar results were seen at day 360. The mean duration of remission was 48.5 ± 6.51 and 49.1 ± 7.42 weeks in the rituximab and conventional strategy groups, respectively (P = 0.41). The average daily glucocorticoid dose did not differ significantly between the treatment groups, nor was there a significant difference in the rates of adverse events.

“On the basis of the results of this trial, the role of rituximab in the therapeutic management of EGPA has been updated,” the authors write.

More information:
Benjamin Terrier et al, Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis, Annals of Internal Medicine (2025). DOI: 10.7326/ANNALS-24-03947

© 2025 HealthDay. All rights reserved.

Citation:
Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis (2025, August 1)
retrieved 1 August 2025
from https://medicalxpress.com/news/2025-08-rituximab-superior-conventional-strategy-eosinophilic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis

For patients with eosinophilic granulomatosis with polyangiitis (EGPA), rituximab is not superior to the conventional remission induction strategy, according to a study published online July 29 in the Annals of Internal Medicine.

Benjamin Terrier, M.D., Ph.D., from Hôpital Cochin in Paris, and colleagues compared rituximab to a conventional strategy for the induction of remission in patients with EGPA in a phase 3, multicenter superiority trial. Patients with a diagnosis of EGPA, newly diagnosed or relapsing disease at the time of screening, were included and randomly assigned in double-blind fashion to receive glucocorticoids plus rituximab versus the conventional strategy of glucocorticoids alone or in combination with cyclophosphamide in severe forms. The primary end point was remission, defined as a Birmingham Vasculitis Activity Score of 0 and a prednisone dose of 7.5 mg/day or less at day 180.

One hundred five participants were randomly assigned. The researchers found that 63.5% and 60.4% of patients in the rituximab and control groups, respectively, achieved the primary end point (relative risk, 1.05; 95% confidence interval, 0.78 to 1.42; P = 0.75).

Similar results were seen at day 360. The mean duration of remission was 48.5 ± 6.51 and 49.1 ± 7.42 weeks in the rituximab and conventional strategy groups, respectively (P = 0.41). The average daily glucocorticoid dose did not differ significantly between the treatment groups, nor was there a significant difference in the rates of adverse events.

“On the basis of the results of this trial, the role of rituximab in the therapeutic management of EGPA has been updated,” the authors write.

More information:
Benjamin Terrier et al, Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis, Annals of Internal Medicine (2025). DOI: 10.7326/ANNALS-24-03947

© 2025 HealthDay. All rights reserved.

Citation:
Rituximab not superior to conventional strategy for eosinophilic granulomatosis with polyangiitis (2025, August 1)
retrieved 1 August 2025
from https://medicalxpress.com/news/2025-08-rituximab-superior-conventional-strategy-eosinophilic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Tags: Health ResearchHealth Research NewsHealth ScienceMedicine ResearchMedicine Research NewsMedicine Science
Previous Post

SpaceX Crew-11 blasts off for the International Space Station

Next Post

How Trump Is Dismantling Biden’s Climate Lawfare Legacy

Related Posts

rural

Study finds living in rural environments in first 5 years of life could be a risk factor for developing type 1 diabetes

August 1, 2025
5
Cannabis use

Study finds rising cannabis use among Black and Hispanic men with chronic illness

August 1, 2025
4
Next Post
President Trump in Scotland

How Trump Is Dismantling Biden’s Climate Lawfare Legacy

  • Trending
  • Comments
  • Latest
Family calls for change after B.C. nurse dies by suicide after attacks on the job

Family calls for change after B.C. nurse dies by suicide after attacks on the job

April 2, 2025
Pioneering 3D printing project shares successes

Product reduces TPH levels to non-hazardous status

November 27, 2024

Police ID man who died after Corso Italia fight

December 23, 2024

Hospital Mergers Fail to Deliver Better Care or Lower Costs, Study Finds todayheadline

December 31, 2024
Harris tells supporters 'never give up' and urges peaceful transfer of power

Harris tells supporters ‘never give up’ and urges peaceful transfer of power

0
Des Moines Man Accused Of Shooting Ex-Girlfriend's Mother

Des Moines Man Accused Of Shooting Ex-Girlfriend’s Mother

0

Trump ‘looks forward’ to White House meeting with Biden

0
Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

Catholic voters were critical to Donald Trump’s blowout victory: ‘Harris snubbed us’

0
Source: Messi bodyguard banned by Leagues Cup

Source: Messi bodyguard banned by Leagues Cup

August 2, 2025
Jessica Pegula stunned in 3 sets in Montreal; Osaka advances

Taylor Fritz, Ben Shelton roll into fourth round in Toronto todayheadline

August 2, 2025

Hilton Grand (HGV) Q2 Revenue Misses 8% todayheadline

August 2, 2025
Ghislaine Maxwell moved to prison camp, Trump says no plea for pardon

Ghislaine Maxwell moved to prison camp, Trump says no plea for pardon todayheadline

August 2, 2025

Recent News

Source: Messi bodyguard banned by Leagues Cup

Source: Messi bodyguard banned by Leagues Cup

August 2, 2025
1
Jessica Pegula stunned in 3 sets in Montreal; Osaka advances

Taylor Fritz, Ben Shelton roll into fourth round in Toronto todayheadline

August 2, 2025
5

Hilton Grand (HGV) Q2 Revenue Misses 8% todayheadline

August 2, 2025
2
Ghislaine Maxwell moved to prison camp, Trump says no plea for pardon

Ghislaine Maxwell moved to prison camp, Trump says no plea for pardon todayheadline

August 2, 2025
6

TodayHeadline is a dynamic news website dedicated to delivering up-to-date and comprehensive news coverage from around the globe.

Follow Us

Browse by Category

  • Africa
  • Asia
  • Basketball
  • Business & Finance
  • Climate Change
  • Crime & Justice
  • Cybersecurity
  • Economic Policies
  • Elections
  • Entertainment
  • Entrepreneurship
  • Environmental Policies
  • Europe
  • Football
  • Gadgets & Devices
  • Health
  • Medical Research
  • Mental Health
  • Middle East
  • Motorsport
  • Olympics
  • Politics
  • Public Health
  • Relationships & Family
  • Science & Environment
  • Software & Apps
  • Space Exploration
  • Sports
  • Stock Market
  • Technology & Startups
  • Tennis
  • Travel
  • Uncategorized
  • Us & Canada
  • Wildlife & Conservation
  • World News

Recent News

Source: Messi bodyguard banned by Leagues Cup

Source: Messi bodyguard banned by Leagues Cup

August 2, 2025
Jessica Pegula stunned in 3 sets in Montreal; Osaka advances

Taylor Fritz, Ben Shelton roll into fourth round in Toronto todayheadline

August 2, 2025
  • Education
  • Lifestyle
  • Technology & Startups
  • About us
  • Contact
  • Advertise with Us
  • Privacy & Policy

© 2024 Todayheadline.co

Welcome Back!

OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Business & Finance
  • Corporate News
  • Economic Policies
  • Entrepreneurship
  • Market Trends
  • Crime & Justice
  • Court Cases
  • Criminal Investigations
  • Cybercrime
  • Legal Reforms
  • Policing
  • Education
  • Higher Education
  • Online Learning
  • Entertainment
  • Awards & Festivals
  • Celebrity News
  • Movies
  • Music
  • Health
  • Fitness & Nutrition
  • Medical Breakthroughs
  • Mental Health
  • Pandemic Updates
  • Lifestyle
  • Fashion & Beauty
  • Food & Drink
  • Home & Living
  • Politics
  • Elections
  • Government Policies
  • International Relations
  • Legislative News
  • Political Parties
  • Africa
  • Asia
  • Europe
  • Middle East
  • Artificial Intelligence
  • Cybersecurity
  • Emerging Technologies
  • Gadgets & Devices
  • Industry Analysis
  • Basketball
  • Football
  • Motorsport
  • Olympics
  • Climate Change
  • Environmental Policies
  • Medical Research
  • Science & Environment
  • Space Exploration
  • Wildlife & Conservation
  • Sports
  • Tennis
  • Technology & Startups
  • Software & Apps
  • Startup Success Stories
  • Startups & Innovations
  • Tech Regulations
  • Venture Capital
  • Uncategorized
  • World News
  • Us & Canada
  • Public Health
  • Relationships & Family
  • Travel
  • Research & Innovation
  • Scholarships & Grants
  • School Reforms
  • Stock Market
  • TV & Streaming
  • Advertise with Us
  • Privacy & Policy
  • About us
  • Contact

© 2024 Todayheadline.co